Search
forResearch 10 of 582
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- Janus Kinase inhibitors in dermatology: a review
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Personalized Medicine in the Field of Inflammatory Skin Disorders
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Efficacy and Potential Mechanisms of Naringin in Atopic Dermatitis
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →